Working… Menu

Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04729608
Recruitment Status : Recruiting
First Posted : January 28, 2021
Last Update Posted : May 20, 2021
GOG Foundation
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Information provided by (Responsible Party):
Aravive, Inc.

Brief Summary:
This is a Phase 3 study of AVB-S6-500 in combination with paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. This is a randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with Pac versus placebo plus Pac.

Condition or disease Intervention/treatment Phase
Platinum-resistant Ovarian Cancer Drug: AVB-S6-500 Drug: Paclitaxel Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Actual Study Start Date : April 22, 2021
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: AVB-S6-500+Pac
Combination of AVB-S6-500 and Pac
Drug: AVB-S6-500
AVB-S6-500 is an experimental drug

Drug: Paclitaxel
Paclitaxel is the standard of care, background therapy
Other Name: Taxol

Placebo Comparator: Placebo+Pac
Placebo-controlled arm with Pac
Drug: Paclitaxel
Paclitaxel is the standard of care, background therapy
Other Name: Taxol

Other: Placebo
Matching placebo

Primary Outcome Measures :
  1. Anti-tumor activity of AVB-S6-500 in combination with Pac measured by progression free survival (PFS) in patients receiving AVB-S6-500+ Pac versus patients receiving Placebo+Pac [ Time Frame: 4 months ]
    PFS is the time interval between randomization and radiologically documented disease progression or death, whichever comes first.

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 20 months ]
    Time following the treatment until death

  2. Objective response rate (ORR) [ Time Frame: 3 months ]
    Proportion of subjects who have a confirmed partial or complete response to therapy relative to baseline as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria

  3. Duration of response (DOR) [ Time Frame: 9 months ]
    Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.

  4. Incidence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: 10 months ]
  5. Quality of Life (QOL) [ Time Frame: 10 months ]
    Subject QOL will be assessed using the Functional Assessment Of Cancer Therapy - Ovarian Cancer (FACT-O) questionnaire, which consists of 4 subscales: physical well-being (7 questions), social/family well-being (7 questions), emotional well-being (6 questions), and functional well-being (7 questions), and 12 additional concerns specific to ovarian cancer. All items are rated on a 5 point scale with 0 "not at all" and 4 "very much". The scoring algorithm allows for eight summary scales: the four core well-being subscales, a subtotal of the 27 core items, a subtotal of the 12 ovarian-specific additional concerns, a grand total of the 39 items, and a trial outcome index (sum of the 17 physical and functional wellbeing items plus the 12 ovarian-specific items).

  6. Clinical benefit rate (CBR) [ Time Frame: 4 months ]
  7. Area under the AVB-S6-500 concentration-time curve. [ Time Frame: 10 months ]
  8. Maximum observed AVB-S6-500 concentration. [ Time Frame: 10 months ]
  9. Time of maximum observed AVB-S6-500 concentration. [ Time Frame: 10 months ]
  10. Half-life of AVB-S6-500. [ Time Frame: 10 months ]
  11. Pharmacodynamic marker assessment [ Time Frame: 10 months ]
    Change from the baseline in GAS6 serum levels.

  12. Anti-drug antibody (ADA) titers [ Time Frame: 10 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed and documented recurrent ovarian, fallopian tube, or peritoneal cancer. Only patients with high-grade serous adenocarcinoma histology are eligible.
  • Aged 18 years or older
  • Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1
  • Platinum-resistant disease (defined as progression within ≤6 months from completion of most recent platinum-containing regimen and calculated from the date of the last administered dose of platinum therapy).
  • Available archived tumor tissue or if archived tissue is not available, a fresh tumor biopsy.
  • Received at least 1 but not more than 4 prior therapy regimens. Note: maintenance therapy OR hormonal therapies should not be counted as a separate therapy.
  • Measurable disease according to RECIST v1.1 criteria

Exclusion Criteria:

  • Tumors in the breast or bone
  • Untreated central nervous system (CNS) metastases (surgery and/or radiotherapy). Subjects requiring corticosteroid therapy for the management of their treated CNS metastases may not be on >10 mg/day prednisone or equivalent or have demonstrated signs or symptoms of neurologic instability for 28 days or less prior to randomization.
  • Primary platinum-refractory disease (defined as progression during or within 4 weeks after completion of the first platinum regimen)
  • Is being treated with concurrent anticancer therapy or other interventional treatments administered for their underlying ovarian cancer.
  • Received prior therapy with PAC in the recurrent setting

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04729608

Layout table for location contacts
Contact: Aravive Clinical Trials 936-355-1910

Layout table for location information
United States, Alabama
University of South Alabama Mitchell Cancer Institute Recruiting
Mobile, Alabama, United States, 36604
United States, Illinois
Dr. Sudarshan K. Sharma, Ltd. Recruiting
Hinsdale, Illinois, United States, 60521
United States, Kentucky
Baptist Health Lexington Recruiting
Lexington, Kentucky, United States, 40503
United States, Louisiana
Willis-Knighton Physician Network Recruiting
Shreveport, Louisiana, United States, 71103
United States, Maine
Maine Medical Partners - Women's Health - Division of Gynecologic Oncology Recruiting
Scarborough, Maine, United States, 04074
United States, Maryland
Greater Baltimore Medical Center Recruiting
Baltimore, Maryland, United States, 21204
United States, New Jersey
The Valley Hospital - Luckow Pavilion Recruiting
Paramus, New Jersey, United States, 07652
Holy Name Medical Center Recruiting
Teaneck, New Jersey, United States, 07666
United States, New Mexico
Optimum Clinical Research Group, LLC Recruiting
Albuquerque, New Mexico, United States, 87109
United States, New York
North Shore Hematology Oncology Assoc. DBA NY Cancer and Blood Specialists Recruiting
Port Jefferson Station, New York, United States, 11776
United States, Ohio
Kettering Cancer Center Recruiting
Kettering, Ohio, United States, 45429
United States, Oklahoma
Oklahoma Cancer Specialists and Research Institute, LLC Recruiting
Tulsa, Oklahoma, United States, 74146
United States, Tennessee
Chattanooga's Program in Women's Oncology Recruiting
Chattanooga, Tennessee, United States, 37403
Sponsors and Collaborators
Aravive, Inc.
GOG Foundation
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Layout table for investigator information
Study Director: Eduardo Pennella, MD Aravive, Inc.
Layout table for additonal information
Responsible Party: Aravive, Inc. Identifier: NCT04729608    
Other Study ID Numbers: AVB500-OC-004
GOG-3059 ( Other Identifier: GOG Foundation )
ENGOT OV66 ( Other Identifier: ENGOT )
First Posted: January 28, 2021    Key Record Dates
Last Update Posted: May 20, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aravive, Inc.:
Ovarian cancer
Platinum resistant
Recurrent ovarian cancer
High-grade serous adenocarcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action